Close Menu

NEW YORK — Exagen on Wednesday reported a 6 percent year-over-year increase in fourth quarter revenues as the company benefitted from its copromotion alliance with Janssen Biotech.

For the three-month period ended Dec. 31, 2019, Exagen's revenues rose to $10.2 million from $9.6 million in the same period a year earlier. Revenues from its autoimmune disease testing portfolio, including its flagship Avise CTD lupus assessment test, were flat year over year at $9.6 million as higher testing volume was offset by lower average selling prices.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.